HK1209319A1 - Methods for treating hepatitis c - Google Patents

Methods for treating hepatitis c

Info

Publication number
HK1209319A1
HK1209319A1 HK15109967.3A HK15109967A HK1209319A1 HK 1209319 A1 HK1209319 A1 HK 1209319A1 HK 15109967 A HK15109967 A HK 15109967A HK 1209319 A1 HK1209319 A1 HK 1209319A1
Authority
HK
Hong Kong
Prior art keywords
methods
treating hepatitis
hepatitis
treating
Prior art date
Application number
HK15109967.3A
Other languages
English (en)
Chinese (zh)
Inventor
Teresa Lok-Chan Ng
Tami J Pilot-Matias
Warren M Kati
Preethi Krishnan
Clarence J Maring
Neeta C Mistry
Thomas J Reisch
Rolf Wagner
Dachun Liu
John K Pratt
Mark A Matulenko
Ryan G Keddy
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49304326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1209319(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of HK1209319A1 publication Critical patent/HK1209319A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK15109967.3A 2012-09-18 2015-10-13 Methods for treating hepatitis c HK1209319A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261702564P 2012-09-18 2012-09-18
PCT/US2013/060103 WO2014047039A1 (en) 2012-09-18 2013-09-17 Methods for treating hepatitis c

Publications (1)

Publication Number Publication Date
HK1209319A1 true HK1209319A1 (en) 2016-04-01

Family

ID=49304326

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109967.3A HK1209319A1 (en) 2012-09-18 2015-10-13 Methods for treating hepatitis c

Country Status (25)

Country Link
US (1) US20140080868A1 (el)
EP (2) EP2897611B1 (el)
JP (4) JP6297044B2 (el)
CN (1) CN104797253A (el)
AU (2) AU2013318302B2 (el)
BR (1) BR112015006037B1 (el)
CA (1) CA2884539C (el)
CY (1) CY1122442T1 (el)
DK (1) DK2897611T3 (el)
ES (1) ES2755089T3 (el)
HK (1) HK1209319A1 (el)
HR (1) HRP20191939T1 (el)
HU (1) HUE046544T2 (el)
LT (1) LT2897611T (el)
MX (2) MX367796B (el)
NZ (1) NZ630581A (el)
PL (1) PL2897611T3 (el)
PT (1) PT2897611T (el)
RS (1) RS59640B1 (el)
RU (1) RU2665365C2 (el)
SG (2) SG11201502095SA (el)
SI (1) SI2897611T1 (el)
TW (1) TWI621436B (el)
WO (1) WO2014047039A1 (el)
ZA (1) ZA201501752B (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2897611T (pt) * 2012-09-18 2019-11-27 Abbvie Inc Métodos para tratamento da hepatite c
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
AU2014239563B2 (en) * 2013-03-14 2016-05-05 Abbvie Inc. Combination of two antivirals for treating hepatitis C
CN106413711A (zh) 2014-04-02 2017-02-15 艾伯维公司 治疗hcv的方法
JP6559701B2 (ja) * 2014-04-02 2019-08-14 アッヴィ・インコーポレイテッド Hcvを処置するための方法
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
KR102637828B1 (ko) * 2015-06-26 2024-02-20 애브비 인코포레이티드 Hcv의 치료를 위한 고형 약제학적 조성물
MX2018000240A (es) * 2015-07-08 2018-03-14 Abbvie Inc Metodos para tratar el vhc.
SG10202002900YA (en) * 2015-07-17 2020-05-28 Abbvie Inc Solid pharmaceutical compositions for treating hcv
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CA3216359A1 (en) 2021-04-07 2022-10-13 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
GB202113944D0 (en) * 2021-09-29 2021-11-10 Univ Liverpool Injectable formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2641859A1 (en) * 2006-02-09 2007-08-16 Schering Corporation Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
SE1450131A1 (sv) * 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
PT2897611T (pt) * 2012-09-18 2019-11-27 Abbvie Inc Métodos para tratamento da hepatite c

Also Published As

Publication number Publication date
HRP20191939T1 (hr) 2020-01-10
TW201412311A (zh) 2014-04-01
PL2897611T3 (pl) 2020-03-31
HUE046544T2 (hu) 2020-03-30
SI2897611T1 (sl) 2019-12-31
MX2015003501A (es) 2015-10-26
MX2019010600A (es) 2020-02-03
AU2018203608A1 (en) 2018-06-14
AU2013318302A1 (en) 2015-04-02
LT2897611T (lt) 2019-12-10
JP2018109035A (ja) 2018-07-12
BR112015006037B1 (pt) 2022-05-17
JP2019194241A (ja) 2019-11-07
ZA201501752B (en) 2016-08-31
ES2755089T3 (es) 2020-04-21
RU2665365C2 (ru) 2018-08-29
WO2014047039A1 (en) 2014-03-27
CA2884539C (en) 2022-06-21
EP2897611A1 (en) 2015-07-29
NZ630581A (en) 2017-02-24
CY1122442T1 (el) 2021-01-27
RU2015114543A (ru) 2016-11-10
US20140080868A1 (en) 2014-03-20
RS59640B1 (sr) 2020-01-31
CA2884539A1 (en) 2014-03-27
EP3597190A1 (en) 2020-01-22
SG10201702248UA (en) 2017-04-27
SG11201502095SA (en) 2015-05-28
AU2018203608B2 (en) 2019-12-19
DK2897611T3 (da) 2019-11-04
JP2015528511A (ja) 2015-09-28
JP6297044B2 (ja) 2018-03-20
AU2013318302B2 (en) 2018-02-22
MX367796B (es) 2019-09-06
JP6556884B2 (ja) 2019-08-07
JP2021054849A (ja) 2021-04-08
TWI621436B (zh) 2018-04-21
EP2897611B1 (en) 2019-07-24
BR112015006037A2 (pt) 2017-07-04
CN104797253A (zh) 2015-07-22
PT2897611T (pt) 2019-11-27

Similar Documents

Publication Publication Date Title
HRP20180237T1 (hr) Metode za liječenje hcv-a
HK1214504A1 (zh) 用於治療貧血的方法
HK1209745A1 (en) Compounds and methods for antiviral treatment
EP2757887A4 (en) PYRROLOPYRIDINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF HIV
HK1209319A1 (en) Methods for treating hepatitis c
HK1198869A1 (en) Combination treatments for hepatitis c
ZA201906339B (en) Methods for treating pruritus
HK1209320A1 (en) Methods for treating hepatitis c
ZA201406172B (en) Compounds and methods for treating leukemia
HK1209040A1 (en) Methods for treating vestibulotoxicity
EP2854774A4 (en) METHODS OF TREATING INSOMNIA
GB201214387D0 (en) Methods for treating plants
GB201209932D0 (en) Improved process